Dosing and Administration

Dosing and administration process for Makena

Makena is given by a healthcare provider subcutaneously via an auto-injector1

  • Begin once weekly (every 7 days) injections of Makena between weeks 160 and 206
  • Continue until 37 weeks (last injection as late as week 366) or delivery, whichever occurs first

Makena dosing schedule1

makena dosing schedule

makena dosing schedule

Guide for how to administer Makena subcutaneous auto-injector

icon

Inspect Makena Auto-Injector

icon

Select and prepare subcutaneous injection site and administer in the back of the upper arm

Posterior of upper arm/triceps area

icon

Remove cap

icon

Position Makena Auto-Injector at a 90 degree angle on injection site

icon

Begin injection: push down and maintain pressure. A full dose is administered in ~15 seconds

icon

Complete injection: remove after viewing window is completely orange

icon

Dispose of auto-injector in a sharps container

makena auto injector device

Please read the Instructions for Use in the full Prescribing Information before administrating Makena for subcutaneous use.

Proper injection technique for Makena subcutaneous auto-injector.
Makena Auto-Injector is HCP administered. This easy-to-follow instructional video reviews the proper technique for administering Makena for subcutaneous use. Please see Instructions for Use before administering Makena using the subcutaneous auto‑injector.

Watch video Download

Help patients understand what to expect

A guide to help set patient expectations for receiving therapy

Help patients understand the treatment schedule

  • Makena injections are given in the back of the upper arm (posterior of upper arm/triceps area) on a weekly basis (every 7 days)
  • Therapy begins between 160 and 206 weeks and continues until 37 weeks (last injection as late as 366 weeks) or delivery, whichever occurs first
  • The injection site rotates from arm to arm each week

Help patients get to know the auto-injector

  • Short, thin, non-visible needle
  • Audible click indicates the device has been activated
  • Injection will take ~15 seconds

Help patients understand what to expect

  • Makena is a thick, oil-based solution
  • Some patients may experience a mild to moderate burning sensation that is transient in nature
  • The most common side effects include injection site reactions (pain, swelling, itching, bruising, or a hard bump), hives, itching, nausea, and diarrhea
  • Allergic reactions, including urticaria, pruritus and angioedema, have been reported with use of Makena or with other products containing castor oil

You are now leaving makenahcp.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Cancel Continue

You are now leaving makenahcp.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Cancel Continue

On April 6, 2023, the U.S. Food and Drug Administration (FDA) issued a final decision ordering the withdrawal of the approval of Makena®. FDA has stated that it recognizes that a limited supply of these drugs has already been distributed, including to physicians’ offices and pharmacies. FDA acknowledges that some health care providers might continue to prescribe or administer that limited remaining supply to their patients. However, we recommend health care practitioners consider FDA’s conclusions.

If you have questions about Makena, please call our Medical Information Call Center at +1-877-411-2510, Monday-Friday from 9:00 AM-7:00 PM EST.

Please see Full Prescribing Information for Makena.

This page will redirect to CovisPharma.com in 30 seconds.

PP-MKN-US-00713 08/23